Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on May 4, 2011. The report discloses a corporate governance event regarding the departure of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial data.
Material Changes
Departure of Director: On May 4, 2011, Odysseas D. Kostas resigned as a director and from all board committees, effective May 5, 2011. The resignation is attributed to other work commitments and is not due to any disagreement with the Company regarding operations, policies, or practices.
Outlook and Management Commentary
- Board Vacancy: The nominating and governance committee is actively searching for a replacement candidate.
- Timing: If a candidate is identified before the annual meeting of stockholders on June 15, 2011, the appointment is likely to be delayed until after that meeting.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Dr. Kostas' departure.
- Confirm the date and outcome of the annual meeting of stockholders scheduled for June 15, 2011.
- Check subsequent filings for the appointment of a new director to fill the vacancy.